ArticleGastro hep advances2025

A Comparison of Intravenous Infliximab Versus Subcutaneous Infliximab on Remission Rates, Safety, Costs, Patient Preferences in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Alejandro Nieto Dominguez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.